The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma

被引:49
作者
Doberstein, Kai [1 ]
Pfeilschifter, Josef [1 ]
Gutwein, Paul [1 ]
机构
[1] Klinikum Goethe Univ, Pharmazentrum Frankfurt, ZAFES, D-60590 Frankfurt, Germany
关键词
HEPATOCYTE GROWTH-FACTOR; ADHESION MOLECULE; BETA-CATENIN; SOLUBLE FORM; CANCER CELLS; APOPTOSIS; L1; METASTASIS; GENE; DISINTEGRIN;
D O I
10.1093/carcin/bgr195
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
ADAM10 is a metalloprotease that plays an important role in the progression and metastasis of various cancers. In the present study, we present compelling evidence that PAX2 can bind to the promotor of ADAM10 and regulate ADAM10 protein expression in renal cancer cells. We further show that ADAM10 is the major sheddase for the constitutive cleavage of L1-CAM and c-Met, two important proteins involved in the progression of renal cancer. The downregulation of ADAM10 led to a more scattered cell phenotype, which was accompanied by the induction of Slug and the loss of E-cadherin, which is observed during epithelial-to-mesenchymal transition (EMT). In addition, the downregulation of ADAM10 reduced the proliferation but induced the migration of renal cancer cells. Notably, the downregulation of PAX2 led to an increased L1-CAM expression, which was accompanied by a massive metalloprotease-mediated release of soluble L1-CAM. Importantly, soluble L1-CAM induced the proliferation of endothelial cells and the migration of renal cancer cells. Finally, we can demonstrate that the silencing of PAX2 led to an L1-CAM-dependent activation of the PI3K/Akt pathway, one important pathway mediating cancer cell survival. In summary, we identified PAX2 as a regulator of L1-CAM and ADAM10, which play crucial roles in the progression of various cancers including renal cell carcinoma and the downregulation of ADAM10 maybe an earlier step in renal cancer development as it seems to be involved in processes of EMT.
引用
收藏
页码:1713 / 1723
页数:11
相关论文
共 58 条
[1]
Allory Y, 2005, CLIN CANCER RES, V11, P1190
[2]
The EUROCARE Study: strengths, limitations and perspectives of population-based, comparative survival studies [J].
Berrino, F. .
ANNALS OF ONCOLOGY, 2003, 14 :V9-V13
[3]
Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[4]
Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells [J].
Buttiglieri, S ;
Deregibus, MC ;
Bravo, S ;
Cassoni, P ;
Chiarle, R ;
Bussolati, B ;
Camussi, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (06) :4136-4143
[5]
Rescue of defective branching nephrogenesis in renal-coloboma syndrome by the caspase inhibitor, Z-VAD-fink [J].
Clark, P ;
Dziarmaga, A ;
Eccles, M ;
Goodyer, P .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (02) :299-305
[6]
Renal-cell carcinoma [J].
Cohen, HT ;
McGovern, FJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2477-2490
[7]
Pax-2 expression in adult renal tumors [J].
Daniel, L ;
Lechevallier, E ;
Giorgi, R ;
Sichez, H ;
Zattara-Cannoni, H ;
Figarella-Branger, D ;
Coulange, C .
HUMAN PATHOLOGY, 2001, 32 (03) :282-287
[8]
L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells [J].
Doberstein, Kai ;
Wieland, Anja ;
Lee, Sophia B. Boyoung ;
Blaheta, Roman A. Alexander ;
Wedel, Steffen ;
Moch, Holger ;
Schraml, Peter ;
Pfeilschifter, Josef ;
Kristiansen, Glen ;
Gutwein, Paul .
CARCINOGENESIS, 2011, 32 (03) :262-270
[9]
DEREGULATION OF PAX-2 EXPRESSION IN TRANSGENIC MICE GENERATES SEVERE KIDNEY ABNORMALITIES [J].
DRESSLER, GR ;
WILKINSON, JE ;
ROTHENPIELER, UW ;
PATTERSON, LT ;
WILLIAMSSIMONS, L ;
WESTPHAL, H .
NATURE, 1993, 362 (6415) :65-67
[10]
DRESSLER GR, 1990, DEVELOPMENT, V109, P787